Yu Y - Search Results

1

Long Noncoding RNA H19: A Novel Therapeutic Target Emerging in Oncology Via Regulating Oncogenic Signaling Pathways.

Wu B, Zhang Y, Yu Y, Zhong C, Lang Q, Liang Z, Lv C, Xu F, Tian Y. Wu B, et al. Among authors: yu y. Front Cell Dev Biol. 2021 Dec 16;9:796740. doi: 10.3389/fcell.2021.796740. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34977037 Free PMC article. Review.

2

HHLA2 promotes tumor progression by long non‑coding RNA H19 in human gallbladder cancer.

Zhang Y, Li H, Lv C, Wu B, Yu Y, Zhong C, Lang Q, Liang Z, Li Y, Shi Y, Zhang J, Xu F, Tian Y. Zhang Y, et al. Among authors: yu y. Int J Oncol. 2022 Sep;61(3):112. doi: 10.3892/ijo.2022.5402. Epub 2022 Aug 3. Int J Oncol. 2022. PMID: 35920182 Free PMC article.

3

Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers.

Shi Y, Li Y, Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Lv C, Han S, Yu Y, Xu F, Tian Y. Shi Y, et al. Among authors: yu y. Int Immunopharmacol. 2022 Sep;110:108968. doi: 10.1016/j.intimp.2022.108968. Epub 2022 Jun 25. Int Immunopharmacol. 2022. PMID: 35764018 Review.

4

KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy.

Li Y, Lv C, Yu Y, Wu B, Zhang Y, Lang Q, Liang Z, Zhong C, Shi Y, Han S, Xu F, Tian Y. Li Y, et al. Among authors: yu y. J Adv Res. 2023 May;47:137-150. doi: 10.1016/j.jare.2022.07.013. Epub 2022 Aug 4. J Adv Res. 2023. PMID: 35933091 Free PMC article. Review.

5

CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.

Li Y, Han S, Wu B, Zhong C, Shi Y, Lv C, Fu L, Zhang Y, Lang Q, Liang Z, Yu Y, Tian Y. Li Y, et al. Among authors: yu y. Front Immunol. 2022 Jul 22;13:951247. doi: 10.3389/fimmu.2022.951247. eCollection 2022. Front Immunol. 2022. PMID: 35935945 Free PMC article.

6

Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.

Lv C, Han S, Wu B, Liang Z, Li Y, Zhang Y, Lang Q, Zhong C, Fu L, Yu Y, Xu F, Tian Y. Lv C, et al. Among authors: yu y. Front Immunol. 2022 Sep 8;13:984172. doi: 10.3389/fimmu.2022.984172. eCollection 2022. Front Immunol. 2022. PMID: 36159808 Free PMC article.

7

Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.

Wu B, Zhong C, Lang Q, Liang Z, Zhang Y, Zhao X, Yu Y, Zhang H, Xu F, Tian Y. Wu B, et al. Among authors: yu y. J Exp Clin Cancer Res. 2021 Aug 25;40(1):267. doi: 10.1186/s13046-021-02068-5. J Exp Clin Cancer Res. 2021. PMID: 34433460 Free PMC article. Review.

8

Cancer Physical Hallmarks as New Targets for Improved Immunotherapy.

Guo H, Zhang T, Yu Y, Xu F. Guo H, et al. Among authors: yu y. Trends Cell Biol. 2021 Jul;31(7):520-524. doi: 10.1016/j.tcb.2021.03.011. Epub 2021 Apr 27. Trends Cell Biol. 2021. PMID: 33926772

9

Targeting the tumor biophysical microenvironment to reduce resistance to immunotherapy.

Zhang T, Jia Y, Yu Y, Zhang B, Xu F, Guo H. Zhang T, et al. Among authors: yu y. Adv Drug Deliv Rev. 2022 Jul;186:114319. doi: 10.1016/j.addr.2022.114319. Epub 2022 May 8. Adv Drug Deliv Rev. 2022. PMID: 35545136 Review.

10

Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma.

Song ZB, Yu Y, Zhang GP, Li SQ. Song ZB, et al. Among authors: yu y. Front Cell Dev Biol. 2021 Oct 5;9:728574. doi: 10.3389/fcell.2021.728574. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34676211 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40,559 results

Search Page

Filters